Curevo rounds up $110M to challenge GSK’s Shringrix, nabs Moncef Slaoui to lead board
In its effort to rival GSK’s shingles vaccine Shingrix, Curevo Vaccine has circled up $110 million and recruited two former GSK leaders to its board.

Mar 17, 2025 0
Mar 17, 2025 0
Mar 17, 2025 0
Mar 17, 2025 0
Mar 16, 2025 0
Mar 16, 2025 0
Mar 16, 2025 0
Feb 9, 2025 0
Feb 9, 2025 0
Feb 9, 2025 0
Feb 9, 2025 0
Mar 17, 2025 0
Mar 17, 2025 0
Mar 17, 2025 0
Mar 14, 2025 0
Or register with email
Feb 9, 2025 0
Feb 10, 2025 0
Feb 11, 2025 0
Feb 9, 2025 0
Feb 9, 2025 0
Feb 13, 2025 0
This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.